In the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A composition[[,]] comprising a construct, wherein the construct comprises:

(a) a CR2 or a fragment thereof, wherein the fragment contains at least the first two N-terminal SCR domains of the CR2 protein; and

(b) a modulator of complement activity.

Claim 2 (original): The composition of claim 1, wherein the construct is a fusion protein.

Claim 3 (canceled).

Claim 4 (currently amended): The composition of ~~any of claims 3~~ claim 1, wherein the modulator of complement activity comprises a complement inhibitor.

Claim 5 (currently amended): The composition of claim 4, wherein the complement inhibitor ~~is~~ comprises the first four SCR domains of decay accelerating factor (DAF).

Claim 6 (currently amended): The composition of claim [[5]] 4, wherein the composition comprises SEQ ID NO. 10.

Claim 7 (currently amended): The composition of claim [[5]] 4, wherein the composition comprises SEQ ID NO. 6.

Claim 8 (currently amended): The composition of claim 4, wherein the complement inhibitor ~~is human~~ comprises CD59.

Claim 9 (original): The composition of claim 8, wherein the composition comprises SEQ ID NO. 12.

Claim 10 (original): The composition of claim 8, wherein the composition comprises SEQ ID NO. 8.

Claim 11 (canceled).

Claim 12 (canceled).

Claim 13 (canceled).

Claim 14 (canceled).

Claim 15 (currently amended): The composition of claim 4, wherein the complement inhibitor ~~is~~ comprises Crry.

Claim 16 (original): The composition of claim 15, wherein the complement inhibitor comprises SEQ ID NO. 17.

Claim 17 (currently amended): The composition of claim [[4]] 8, wherein the complement inhibitor is murine CD59 or human CD59.

Claim 18 (canceled).

Claim 19 (currently amended): The composition of claim [[18]] 1, wherein the modulator of complement activity comprises a complement activator.

Claim 20 (canceled).

Claim 21 (canceled).

Claim 22 (canceled).

Claim 23 (canceled).

Claim 24 (canceled).

Claim 25 (canceled).

Claim 26 (canceled).

Claim 27 (currently amended): The composition of claim 19, wherein the complement activator ~~is~~ comprises CVF.

Claim 28 (original): The composition of claim 27, wherein the complement activator comprises SEQ ID NO. 24.

Claim 29 (original): The composition of claim 1, wherein the construct is an immunoconjugate.

Claim 30 (currently amended): A method of treating a condition affected by complement in a subject comprising administering to the subject the composition of any of claims ~~1-29~~ 1, 2, 4, 19, or 52.

Claim 31 (original): The method of claim 30, wherein the condition is a cancer.

Claim 32 (canceled).

Claim 33 (currently amended): The method of claim 30, wherein the condition is selected from the group consisting of a viral infection, a bacterial infection, a parasitic infection, and a fungal infection.

Claim 34 (canceled).

Claim 35 (canceled).

Claim 36 (canceled).

Claim 37 (canceled).

Claim 38 (canceled).

Claim 39 (canceled).

Claim 40 (canceled).

Claim 41 (original): The method of claim 30, wherein the condition is an inflammatory condition.

Claim 42 (canceled).

Claim 43 (canceled).

Claim 44 (canceled).

Claim 45 (canceled).

Claim 46 (currently amended): A method of reducing complement-mediated damage comprising administering to a subject the composition of any of claims ~~1-27 or 29~~ 1, 2, 4, or 52.

Claim 47 (currently amended): A method of enhancing complement-mediated damage comprising administering to a subject the composition of any of claims ~~1, 2, or 18-29~~ 1, 2, 19 or 52.

Claim 48 (new): The composition of claim 2, wherein the CR2 or a fragment thereof is fused to the N-terminus of the modulator of complement activity.

Claim 49 (new): The composition of claim 2, wherein the CR2 or a fragment thereof is fused to the C-terminus of the modulator of complement activity.

Claim 50 (new): The composition of claim 1, wherein the CR2 or a fragment thereof comprises a full-length CR2 protein.

Claim 51 (new): The composition of claim 1, wherein the CR2 or a fragment thereof comprises the four N-terminal SCR domains of the CR2 protein.

Claim 52 (new). The composition of claim 1, wherein the modulator of complement activity is selected from the group consisting of Crry, CD59, DAF, CVF, and a fragment thereof.

Claim 53 (new): The composition of claim 4, wherein the complement inhibitor comprises the first five N-terminal SCR domains of Crry.

Claim 54 (new): The composition of claim 4, wherein the complement inhibitor comprises the extracellular region of CD59.

Claim 55 (new): A method of targeting a modulator of complement activity to a site of complement activation in a subject by administering to the subject a composition of any of claims 1, 2, 4, 8, 17, 19 or 52.

Claim 56 (new): A method of treating an inflammatory condition in a subject by administering to the subject a composition of any of claims 1, 2, 4, 8, 17 or 52.

Claim 57 (new): The method of claim 56, wherein the inflammatory condition is stroke.

Claim 58 (new): The method of claim 56, wherein the inflammatory condition is ischemia reperfusion injury.

Claim 59 (new): A nucleotide sequence encoding a fusion protein of claim 2.

Claim 60 (new): A composition comprising a construct, wherein the construct comprises a targeting vehicle for proximal tubule targeting and a complement inhibitor.

Claim 61 (new): The composition of claim 60, wherein the construct is a fusion protein.

Claim 62 (new): The composition of claim 60, wherein the targeting vehicle is an antibody.

Claim 63 (new): The composition of claim 62, wherein the antibody is mAb K9/9.

Claim 64 (new): The composition of claim 62, wherein the antibody is a human antibody.

Claim 65 (new): The composition of claim 62, wherein the antibody is a humanized antibody.

Claim 66 (new): The composition of claim 60, wherein the complement inhibitor is selected from the group consisting of DAF, CD59, Crry, CR1, and MCP.

Claim 67 (new): The composition of claim 66, wherein the complement inhibitor is Crry.

Claim 68 (new): The composition of claim 67, wherein the targeting vehicle is mAb K9/9.

Claim 69 (new): The composition of claim 66, wherein the complement inhibitor is CD59.

Claim 70 (new): The composition of claim 69, wherein the targeting vehicle is mAb K9/9.

Claim 71 (new): A method of treating a renal condition affected by complement in a subject comprising administering to the subject the composition of any of claims 60-70.

Claim 72 (new): The method of claim 71, wherein the renal condition is tubulointestinal injury.

Claim 73 (new): The method of claim 72, wherein the renal condition is proteinuria induced tubulointestinal injury.